126 related articles for article (PubMed ID: 7924828)
1. Linomide, a new treatment for autoimmune diseases: the potential in type 1 diabetes.
Slavin S; Sidi H; Weiss L; Rosenman E; Kalland T; Gross D
Diabetes Metab Rev; 1993 Dec; 9(4):311-5. PubMed ID: 7924828
[No Abstract] [Full Text] [Related]
2. The immunomodulator Linomide: role in treatment and prevention of autoimmune diabetes mellitus.
Gross DJ; Weiss L; Reibstein I; Hedlund G; Dahlén E; Rapoport MJ; Slavin S
Int Immunopharmacol; 2001 Jun; 1(6):1131-9. PubMed ID: 11407307
[TBL] [Abstract][Full Text] [Related]
3. Prevention and treatment of type I diabetes in NOD mice by linomide.
Slavin S; Gross D; Weiss L
Transplant Proc; 1995 Dec; 27(6):3240. PubMed ID: 8539933
[No Abstract] [Full Text] [Related]
4. Linomide does not prevent spontaneous autoimmune thyroiditis in NOD mice.
Hartoft-Nielsen ML; Rasmussen AK; Kaas A; Bock T; Buschard K; Feldt-Rasmussen U
Autoimmunity; 2001; 33(2):79-84. PubMed ID: 11264786
[TBL] [Abstract][Full Text] [Related]
5. Prevention of autoimmune diabetes by linomide in nonobese diabetic (NOD) mice is associated with up-regulation of the TCR-mediated activation of p21(ras).
Rapoport MJ; Weiss L; Mor A; Bistritzer T; Ramot Y; Slavin S
J Immunol; 1996 Nov; 157(10):4721-5. PubMed ID: 8906854
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of autoimmune disease by the immunomodulator linomide correlates with the ability to activate macrophages.
Dahlén E; Andersson M; Dawe K; Tellander AC; Brunmark C; Björk A; Hedlund G
Autoimmunity; 2000 Oct; 32(3):199-211. PubMed ID: 11092700
[TBL] [Abstract][Full Text] [Related]
7. The effect of linomide, an immunoregulator in experimental autoimmune diseases, on humoral antibody responses in mice.
Morecki S; Nabet C; Falk P; Fridkis-Hareli M; Pecht I; Mond JJ; Slavin S
Autoimmunity; 1997; 25(4):223-32. PubMed ID: 9344330
[TBL] [Abstract][Full Text] [Related]
8. Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug.
Gross DJ; Sidi H; Weiss L; Kalland T; Rosenmann E; Slavin S
Diabetologia; 1994 Dec; 37(12):1195-201. PubMed ID: 7895948
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide).
Karussis DM; Lehmann D; Slavin S; Vourka-Karussis U; Mizrachi-Koll R; Ovadia H; Kalland T; Abramsky O
Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6400-4. PubMed ID: 8341645
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of diabetes in NOD mice with advanced disease by islet isografts following immunoregulation with Linomide (quinoline-3-carboxamide).
Slavin S; Weiss L; Xia W; Gross DJ
Cell Transplant; 1996; 5(6):627-30. PubMed ID: 8951220
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide.
Karussis DM; Lehmann D; Slavin S; Vourka-Karussis U; Mizrachi-Koll R; Ovadia H; Ben-Nun A; Kalland T; Abramsky O
Ann Neurol; 1993 Nov; 34(5):654-60. PubMed ID: 8239559
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulation of autoimmunity by linomide.
Karussis DM; Lehmann D; Slavin S; Kalland T; Vourka-Karussis U; Mizrachi-Koll R; Ovadia H; Abramsky O
Isr J Med Sci; 1995 Jan; 31(1):38-41. PubMed ID: 7836046
[No Abstract] [Full Text] [Related]
13. Amelioration of diabetes in nonobese diabetic mice with advanced disease by linomide-induced immunoregulation combined with Reg protein treatment.
Gross DJ; Weiss L; Reibstein I; van den Brand J; Okamoto H; Clark A; Slavin S
Endocrinology; 1998 May; 139(5):2369-74. PubMed ID: 9564847
[TBL] [Abstract][Full Text] [Related]
14. The inhibitory effect in experimental autoimmune encephalomyelitis by the immunomodulatory drug Linomide (PNU-212616) is not mediated via release of endogenous glucocorticoids.
Pekarski O; Björk J; Hedlund G; Andersson G
Autoimmunity; 1998; 28(4):235-41. PubMed ID: 9892505
[TBL] [Abstract][Full Text] [Related]
15. Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial.
Coutant R; Landais P; Rosilio M; Johnsen C; Lahlou N; Chatelain P; Carel JC; Ludvigsson J; Boitard C; Bougnères PF
Diabetologia; 1998 Sep; 41(9):1040-6. PubMed ID: 9754822
[TBL] [Abstract][Full Text] [Related]
16. Cytokine production in Linomide-treated nod mice and the potential role of a Th (1)/Th(2) shift on autoimmune and anti-inflammatory processes.
Weiss L; Barak V; Zeira M; Abdul-Hai A; Raibstein I; Reich S; Hirschfeld E; Gross D; Slavin S
Cytokine; 2002 Jul; 19(2):85-93. PubMed ID: 12182843
[TBL] [Abstract][Full Text] [Related]
17. Linomide suppresses chronic-relapsing experimental autoimmune encephalomyelitis in DA rats.
Zhu J; Diab A; Mustafa M; Levi M; Wahren B; Björk J; Hedlund G
J Neurol Sci; 1998 Oct; 160(2):113-20. PubMed ID: 9849793
[TBL] [Abstract][Full Text] [Related]
18. Effect of the synthetic immunomodulator, linomide, on experimental models of thyroiditis.
Hutchings P; Hedlund G; Dawe K; Howlett S; Cooke A
Immunology; 1999 Mar; 96(3):340-7. PubMed ID: 10233714
[TBL] [Abstract][Full Text] [Related]
19. Failure of treatment with Linomide or oral myelin tolerization to ameliorate demyelination in a viral model of multiple sclerosis.
Drescher KM; Rivera-Quinones C; Lucchinetti CF; Rodriguez M
J Neuroimmunol; 1998 Aug; 88(1-2):111-9. PubMed ID: 9688332
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.
Jönsson S; Andersson G; Fex T; Fristedt T; Hedlund G; Jansson K; Abramo L; Fritzson I; Pekarski O; Runström A; Sandin H; Thuvesson I; Björk A
J Med Chem; 2004 Apr; 47(8):2075-88. PubMed ID: 15056005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
